Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTIQ vs DIASTAT ACUDIAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
Status epilepticus,Acute repetitive seizures,Adjunctive treatment for epilepsy
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Terminal elimination half-life: 20-50 hours in adults; prolonged in elderly and patients with hepatic impairment (up to 100 hours).
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Hepatic via CYP2C19, CYP3A4, and CYP2B6; major metabolite is N-desmethyldiazepam (active); also forms oxazepam and temazepam.
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
Primarily renal (urinary) as glucuronide conjugates and unchanged drug; <2% excreted unchanged in feces.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
97-99% bound primarily to albumin.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
0.8-1.4 L/kg (adults); reflects extensive distribution into tissues including brain.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
Rectal gel: 80-100% relative to intravenous administration.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
No specific dose adjustment provided in labeling; use with caution in severe renal impairment (Cr Cl < 10 m L/min) due to propylene glycol content.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
Dose reduction may be necessary in Child-Pugh Class C cirrhosis; avoid in severe hepatic impairment due to decreased clearance and propylene glycol accumulation.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
2 to 5 years: 0.5 mg/kg rectally; 6 to 11 years: 0.3 mg/kg; 12 years and older: 0.2 mg/kg. Dose per treatment episode not to exceed 20 mg.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Start at lower end of dosing range (2.5-5 mg) due to increased sensitivity and decreased clearance; monitor for excessive sedation and respiratory depression.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Concomitant use with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for patients with inadequate response to alternatives.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Risk of respiratory depression, particularly with high doses or in elderly/chronically ill; tolerance and dependence; withdrawal symptoms; may impair cognitive and motor functions; should not be abruptly discontinued.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Hypersensitivity to diazepam or benzodiazepines; narrow-angle glaucoma; severe respiratory insufficiency; myasthenia gravis; concomitant use with opioids (except for palliative care).
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
Grapefruit and grapefruit juice may increase diazepam levels and risk of toxicity; avoid concurrent consumption. Alcohol potentiates CNS depression and should be avoided. No other significant food interactions reported.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters, chronic use may lead to fetal benzodiazepine exposure; high doses near term can cause neonatal withdrawal (hypertonia, irritability, tremors, poor feeding) and 'floppy infant syndrome' (hypotonia, lethargy, respiratory depression). No known structural teratogenicity in later trimesters.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
Diazepam is excreted into breast milk; M/P ratio is approximately 0.1-0.3. Relative infant dose estimated at 1-10% of maternal weight-adjusted dose. Neonatal accumulation possible due to long half-life (50-100 hours in preterm neonates). Breastfeeding is not recommended during chronic use due to risks of sedation, poor feeding, and withdrawal. Short-term, single-dose use may be acceptable with monitoring.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
Pregnancy increases volume of distribution and decreases albumin concentration, potentially reducing diazepam peak levels. However, drug clearance is unchanged or slightly decreased. Dose adjustments are individually determined based on clinical response; no fixed rule. Lower initial doses may be considered in third trimester due to enhanced drug sensitivity. After delivery, reduce dose to pre-pregnancy levels.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
DIASTAT ACUDIAL is a diazepam rectal gel formulation used for acute repetitive seizures. Administer rectally; position patient on side to reduce aspiration risk. Do not administer more than 5 doses per month or more than 2 doses per single seizure episode. Monitor respiratory depression, especially with concurrent CNS depressants. Onset of action is 5-15 minutes; if seizure persists beyond 15 minutes, seek emergency medical attention. Avoid use in patients with acute narrow-angle glaucoma or severe liver disease.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
Use exactly as prescribed; do not exceed recommended doses.,Insert the rectal gel tip gently and hold buttocks together for 1-2 minutes after administration.,Keep a seizure diary to track episodes and medication use.,Do not drive or operate machinery until you know how this medication affects you.,Avoid alcohol and other CNS depressants while using this drug.,Seek medical help if seizures worsen or if breathing difficulties occur.,Store at room temperature away from light and moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTIQ vs DIASTAT ACUDIAL, answered by our medical review team.
ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. DIASTAT ACUDIAL is a Benzodiazepine Anticonvulsant that works by Binds to GABA-A receptors, enhancing GABA effects and increasing chloride ion conductance, leading to neuronal hyperpolarization and inhibition of seizure activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTIQ and DIASTAT ACUDIAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. The standard adult dose of DIASTAT ACUDIAL is: 2.5 mg to 20 mg rectally, as a single dose for acute seizure clusters; may repeat once after 4-12 hours if needed. Maximum: 20 mg per treatment episode.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTIQ and DIASTAT ACUDIAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. DIASTAT ACUDIAL is classified as Category C. DIASTAT ACUDIAL (diazepam) crosses the placenta. First trimester exposure is associated with a small increased risk of oral clefts (odds ratio ~1.5). In second and third trimesters. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.